Evaluating susceptibility to pancreatic cancer

ASCO provisional clinical opinion

Elena M. Stoffel, Shannon E. McKernin, Randall Brand, Marcia Canto, Michael Goggins, Cassadie Moravek, Arun Nagarajan, Gloria M Petersen, Diane M. Simeone, Matthew Yurgelun, Alok A. Khorana

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

PURPOSE: An ASCO provisional clinical opinion (PCO) offers timely clinical direction to ASCO's membership and other health care providers. This PCO addresses identification and management of patients and family members with possible predisposition to pancreatic adenocarcinoma. METHODS: ASCO convened an Expert Panel and conducted a systematic review of the literature published from January 1998 to June 2018. Results of the databases searched were supplemented with hand searching of the bibliographies of systematic reviews and selected seminal articles and contributions from Expert Panel members' curated files. PROVISIONAL CLINICAL OPINION All: patients diagnosed with pancreatic adenocarcinoma should undergo assessment of risk for hereditary syndromes known to be associated with an increased risk for pancreatic adenocarcinoma. Assessment of risk should include a comprehensive review of family history of cancer. Individuals with a family history of pancreatic cancer affecting two first-degree relatives meet criteria for familial pancreatic cancer (FPC). Individuals (cancer affected or unaffected) with a family history of pancreatic cancer meeting criteria for FPC, those with three or more diagnoses of pancreatic cancer in same side of the family, and individuals meeting criteria for other genetic syndromes associated with increased risk for pancreatic cancer have an increased risk for pancreatic cancer and are candidates for genetic testing. Germline genetic testing for cancer susceptibility may be discussed with individuals diagnosed with pancreatic cancer, even if family history is unremarkable. Benefits and limitations of pancreatic cancer screening should be discussed with individuals whose family history meets criteria for FPC and/or genetic susceptibility to pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)153-164
Number of pages12
JournalJournal of Clinical Oncology
Volume37
Issue number2
DOIs
StatePublished - Jan 10 2019

Fingerprint

Pancreatic Neoplasms
Adenocarcinoma
Genetic Testing
Neoplasms
Bibliography
Genetic Predisposition to Disease
Early Detection of Cancer
Health Personnel
Databases

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Stoffel, E. M., McKernin, S. E., Brand, R., Canto, M., Goggins, M., Moravek, C., ... Khorana, A. A. (2019). Evaluating susceptibility to pancreatic cancer: ASCO provisional clinical opinion. Journal of Clinical Oncology, 37(2), 153-164. https://doi.org/10.1200/JCO.18.01489

Evaluating susceptibility to pancreatic cancer : ASCO provisional clinical opinion. / Stoffel, Elena M.; McKernin, Shannon E.; Brand, Randall; Canto, Marcia; Goggins, Michael; Moravek, Cassadie; Nagarajan, Arun; Petersen, Gloria M; Simeone, Diane M.; Yurgelun, Matthew; Khorana, Alok A.

In: Journal of Clinical Oncology, Vol. 37, No. 2, 10.01.2019, p. 153-164.

Research output: Contribution to journalArticle

Stoffel, EM, McKernin, SE, Brand, R, Canto, M, Goggins, M, Moravek, C, Nagarajan, A, Petersen, GM, Simeone, DM, Yurgelun, M & Khorana, AA 2019, 'Evaluating susceptibility to pancreatic cancer: ASCO provisional clinical opinion', Journal of Clinical Oncology, vol. 37, no. 2, pp. 153-164. https://doi.org/10.1200/JCO.18.01489
Stoffel EM, McKernin SE, Brand R, Canto M, Goggins M, Moravek C et al. Evaluating susceptibility to pancreatic cancer: ASCO provisional clinical opinion. Journal of Clinical Oncology. 2019 Jan 10;37(2):153-164. https://doi.org/10.1200/JCO.18.01489
Stoffel, Elena M. ; McKernin, Shannon E. ; Brand, Randall ; Canto, Marcia ; Goggins, Michael ; Moravek, Cassadie ; Nagarajan, Arun ; Petersen, Gloria M ; Simeone, Diane M. ; Yurgelun, Matthew ; Khorana, Alok A. / Evaluating susceptibility to pancreatic cancer : ASCO provisional clinical opinion. In: Journal of Clinical Oncology. 2019 ; Vol. 37, No. 2. pp. 153-164.
@article{877ce954dfeb4230a48a89f3a7c6d4df,
title = "Evaluating susceptibility to pancreatic cancer: ASCO provisional clinical opinion",
abstract = "PURPOSE: An ASCO provisional clinical opinion (PCO) offers timely clinical direction to ASCO's membership and other health care providers. This PCO addresses identification and management of patients and family members with possible predisposition to pancreatic adenocarcinoma. METHODS: ASCO convened an Expert Panel and conducted a systematic review of the literature published from January 1998 to June 2018. Results of the databases searched were supplemented with hand searching of the bibliographies of systematic reviews and selected seminal articles and contributions from Expert Panel members' curated files. PROVISIONAL CLINICAL OPINION All: patients diagnosed with pancreatic adenocarcinoma should undergo assessment of risk for hereditary syndromes known to be associated with an increased risk for pancreatic adenocarcinoma. Assessment of risk should include a comprehensive review of family history of cancer. Individuals with a family history of pancreatic cancer affecting two first-degree relatives meet criteria for familial pancreatic cancer (FPC). Individuals (cancer affected or unaffected) with a family history of pancreatic cancer meeting criteria for FPC, those with three or more diagnoses of pancreatic cancer in same side of the family, and individuals meeting criteria for other genetic syndromes associated with increased risk for pancreatic cancer have an increased risk for pancreatic cancer and are candidates for genetic testing. Germline genetic testing for cancer susceptibility may be discussed with individuals diagnosed with pancreatic cancer, even if family history is unremarkable. Benefits and limitations of pancreatic cancer screening should be discussed with individuals whose family history meets criteria for FPC and/or genetic susceptibility to pancreatic cancer.",
author = "Stoffel, {Elena M.} and McKernin, {Shannon E.} and Randall Brand and Marcia Canto and Michael Goggins and Cassadie Moravek and Arun Nagarajan and Petersen, {Gloria M} and Simeone, {Diane M.} and Matthew Yurgelun and Khorana, {Alok A.}",
year = "2019",
month = "1",
day = "10",
doi = "10.1200/JCO.18.01489",
language = "English (US)",
volume = "37",
pages = "153--164",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "2",

}

TY - JOUR

T1 - Evaluating susceptibility to pancreatic cancer

T2 - ASCO provisional clinical opinion

AU - Stoffel, Elena M.

AU - McKernin, Shannon E.

AU - Brand, Randall

AU - Canto, Marcia

AU - Goggins, Michael

AU - Moravek, Cassadie

AU - Nagarajan, Arun

AU - Petersen, Gloria M

AU - Simeone, Diane M.

AU - Yurgelun, Matthew

AU - Khorana, Alok A.

PY - 2019/1/10

Y1 - 2019/1/10

N2 - PURPOSE: An ASCO provisional clinical opinion (PCO) offers timely clinical direction to ASCO's membership and other health care providers. This PCO addresses identification and management of patients and family members with possible predisposition to pancreatic adenocarcinoma. METHODS: ASCO convened an Expert Panel and conducted a systematic review of the literature published from January 1998 to June 2018. Results of the databases searched were supplemented with hand searching of the bibliographies of systematic reviews and selected seminal articles and contributions from Expert Panel members' curated files. PROVISIONAL CLINICAL OPINION All: patients diagnosed with pancreatic adenocarcinoma should undergo assessment of risk for hereditary syndromes known to be associated with an increased risk for pancreatic adenocarcinoma. Assessment of risk should include a comprehensive review of family history of cancer. Individuals with a family history of pancreatic cancer affecting two first-degree relatives meet criteria for familial pancreatic cancer (FPC). Individuals (cancer affected or unaffected) with a family history of pancreatic cancer meeting criteria for FPC, those with three or more diagnoses of pancreatic cancer in same side of the family, and individuals meeting criteria for other genetic syndromes associated with increased risk for pancreatic cancer have an increased risk for pancreatic cancer and are candidates for genetic testing. Germline genetic testing for cancer susceptibility may be discussed with individuals diagnosed with pancreatic cancer, even if family history is unremarkable. Benefits and limitations of pancreatic cancer screening should be discussed with individuals whose family history meets criteria for FPC and/or genetic susceptibility to pancreatic cancer.

AB - PURPOSE: An ASCO provisional clinical opinion (PCO) offers timely clinical direction to ASCO's membership and other health care providers. This PCO addresses identification and management of patients and family members with possible predisposition to pancreatic adenocarcinoma. METHODS: ASCO convened an Expert Panel and conducted a systematic review of the literature published from January 1998 to June 2018. Results of the databases searched were supplemented with hand searching of the bibliographies of systematic reviews and selected seminal articles and contributions from Expert Panel members' curated files. PROVISIONAL CLINICAL OPINION All: patients diagnosed with pancreatic adenocarcinoma should undergo assessment of risk for hereditary syndromes known to be associated with an increased risk for pancreatic adenocarcinoma. Assessment of risk should include a comprehensive review of family history of cancer. Individuals with a family history of pancreatic cancer affecting two first-degree relatives meet criteria for familial pancreatic cancer (FPC). Individuals (cancer affected or unaffected) with a family history of pancreatic cancer meeting criteria for FPC, those with three or more diagnoses of pancreatic cancer in same side of the family, and individuals meeting criteria for other genetic syndromes associated with increased risk for pancreatic cancer have an increased risk for pancreatic cancer and are candidates for genetic testing. Germline genetic testing for cancer susceptibility may be discussed with individuals diagnosed with pancreatic cancer, even if family history is unremarkable. Benefits and limitations of pancreatic cancer screening should be discussed with individuals whose family history meets criteria for FPC and/or genetic susceptibility to pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=85058315996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058315996&partnerID=8YFLogxK

U2 - 10.1200/JCO.18.01489

DO - 10.1200/JCO.18.01489

M3 - Article

VL - 37

SP - 153

EP - 164

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 2

ER -